Progenity, Inc.

52 articles with Progenity, Inc.

• Progenity Announces Patent Granted by USPTO for its Preeclampsia Rule-Out Test

  9/14/2021

  Progenity, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,112,403 for assessment of preeclampsia using assays for free and dissociated placental growth factor.

• Progenity to Participate in Two Upcoming September 2021 Investor Conferences

  9/3/2021

  Progenity, Inc., an innovative biotechnology company, announced that the company will participate in two upcoming virtual investor conferences

• Progenity Announces Closing of $40 Million Underwritten Public Offering - Aug 24, 2021

  8/24/2021

  Progenity, Inc., an innovative biotechnology company, announced the closing of its previously announced underwritten public offering of 40,000,000 shares of its common stock and warrants to purchase up to 40,000,000 shares of its common stock, at a public offering price of $1.00 per share and associated warrant.

• Progenity Announces Pricing of $40 Million Public Offering of Common Stock and Warrants

  8/20/2021

  Progenity, Inc., an innovative biotechnology company, announced the pricing of its previously announced underwritten public offering of 40,000,000 shares of its common stock and warrants to purchase up to 40,000,000 shares of its common stock.

• Progenity Announces Proposed Underwritten Public Offering of Common Stock and Warrants - Aug 19, 2021

  8/19/2021

  Progenity, Inc., an innovative biotechnology company, announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.

• Progenity Provides Corporate Update and Reports Second Quarter 2021 Financial Results

  8/12/2021

  Progenity, Inc., a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics, provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

• Progenity to Report Second Quarter 2021 Financial Results and Provide Corporate Update

  8/5/2021

  Progenity, Inc., an innovative biotechnology company, announced that it will report second quarter 2021 financial results on Thursday, August 12, 2021 after the close of financial markets.

• Progenity Announces Successful Completion of Clinical Validation Study and Achievement of the Primary Endpoint for its Preeclampsia Rule-Out TestThe company’s Preecludia™ test performed strongly in a broad, intended-use population

  7/29/2021

  Progenity, Inc., an innovative biotechnology company, announced successful completion of the validation study for its Preecludia™ rule-out test for preeclampsia and achievement of the primary endpoint of the study protocol.

• 

  BioSpace Movers & Shakers, July 2

  7/2/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Progenity Announces Appointment of Surbhi Sarna to its Board of Directors

  6/30/2021

  Progenity, Inc. announced the appointment of Surbhi Sarna to its board of directors effective July 1, 2021.

• Progenity Establishes Inflammatory Bowel Disease Clinical Advisory Board

  6/17/2021

  Progenity, Inc. today announced the formation of its Inflammatory Bowel Disease Clinical Advisory Board.

• Progenity to Participate in the Raymond James 2021 Human Health Innovation Conference

  6/15/2021

  Progenity, Inc. will participate in a fireside chat at the virtual Raymond James 2021 Human Health Innovation Conference at 10:40 a.m. ET / 7:40 a.m. PT on Tuesday, June 22, 2021.

• Progenity Announces $40 Million Private Placement

  6/10/2021

  Progenity, Inc. today announced that it has entered into a definitive securities purchase agreement with two leading healthcare-focused investment funds for the sale of units consisting of shares of common stock.

• Progenity Launches Strategic Transformation into Biotech Company, Eliminating Costs of Progenity Genetics Lab and Focusing on Robust, Innovative R&D Pipeline

  6/2/2021

  Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations – from more than $180 million currently to targeted operating expenses of ~$50 million in 2022

• Progenity Provides Results from Key Study for Its Targeted Therapeutics Program

  5/26/2021

  Progenity , Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced results from a further study for the company’s Targeted Therapeutics program. The study evaluated delivery of Progenity’s PGN-001 (adalimumab) drug substance directly to the colon in a preclinical model of colitis.

• Sean Lavin, MD, Joins Progenity as Vice President, Business Development, Strategy, and Investor Relations

  5/25/2021

  Progenity, Inc., an innovative biotechnology company, announced the appointment of Sean Lavin, M.D. as Vice President, Business Development, Strategy, and Investor Relations.

• Progenity Joins Global Call to Raise Awareness of Preeclampsia in Pregnancy on World Preeclampsia Day – May 22ndProvides educational resources for both patients and healthcare providers

  5/21/2021

  Progenity, Inc . (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products in women’s health, joins the global call to raise awareness of preeclampsia in pregnancy on World Preeclampsia Day, on Saturday, May 22. 

• Progenity Provides Corporate Update and Reports First Quarter 2021 Financial Results

  5/13/2021

  Announced pre-validation data for its Preecludia™ test showed strong performance consistent with verification study and demonstrated commercial laboratory systems readiness

• Progenity Provides Preliminary Results from Key Studies for its Targeted Therapeutics Program

  5/12/2021

  Progenity , Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced preliminary results, subject to final audited study reports by its contract research organization (CRO), from two key studies for the Company’s Targeted Therapeutics program. The studies involved both the first functional clinical study of the Drug Delivery System (DDS), and the first preclinical study of PGN-600 (liquid tofacitinib delivered by DDS), one of the Co

• Progenity Receives Funding from Crohn’s & Colitis Foundation IBD Ventures Fund to Develop Drug Delivery System for IBD

  5/11/2021

  Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, announced today that it has received funding from the Crohn’s & Colitis Foundation’s IBD Ventures program to further develop Progenity’s first-in-class oral Drug Delivery System (DDS) for delivery of targeted therapeutics for inflammatory bowel disease (IBD).